Shorted
Csl logo
CSL
Pharmaceuticals, Biotechnology & Life Sciences

CSL

Short interest
1.15%
−0.28 pp 30d
as of 13 Oct 2026
Reported shorts
5.5M
Shares on issue
479.884M

CSL (CSL) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
1d ago

Can CSL (ASX:CSL) Extend Its Remarkable Rebound?

Highlights CSL rose on Friday and is now solidly higher for the year. The biotech giant has more than doubled from its early June low. Healthcare was the best-performing ASX sector this week, rising strongly. CSL (ASX:CSL), the plasma therapies and vaccines group that is one of Australia's largest companies, has staged one of the sharpest recoveries among blue chips this year. Its gains continued on Friday as investors piled into healthcare stocks. The rally keeps CSL front of mind for follow...

Continue reading
Kalkine
Neutral
3d ago

Which moves is CSL (ASX:CSL) making in its reset phase?

Highlights CSL has entered a co-development agreement for an investigational kidney and liver therapy The company is changing the technology platform used across its US plasma centres A corporate bond issue has been completed to refinance existing debt A run of announcements in quick succession has given the market a clearer view of how a heavyweight of the Australian market is rebuilding after a difficult year. CSL Limited (ASX:CSL), the Melbourne-headquartered global biotechnology group beh...

Continue reading
Kalkine
Positive
8 Oct

CSL Limited to Finalize Haemonetics Plasmapheresis Platform Deployment at U.S. Plasma Centres by 2027 End

CSL Limited (ASX:CSL) has revealed plans to deepen its collaboration with Haemonetics Corporation, aiming to complete the installation of Haemonetics' newest plasmapheresis platform across all its U.S. plasma collection centres by the close of 2027. Key Points CSL is broadening its partnership with Haemonetics Corporation to implement a new plasmapheresis platform throughout its U.S. plasma collection facilities. The deployment of Haemonetics' latest generation plasmapheresis technology is pr...

Continue reading
Kalkine
Positive
5 Oct

Could CSL (ASX:CSL) Extend Its Healthcare Recovery?

Highlight CSL (ASX:CSL) has entered an exclusive global partnership with Alentis Therapeutics for lixudebart. The investigational treatment is being developed for a rare autoimmune kidney condition and could also be explored across other kidney and liver diseases. CSL's existing plasma therapies, newer products and nephrology portfolio remain central to its longer-term business development. CSL Limited (ASX:CSL) has expanded its pharmaceutical development pipeline through an exclusive global p...

Continue reading
Kalkine
Neutral
25 Sept

Does CSL's Candid Annual Report Mark a Turning Point (ASX:CSL)?

Highlights The board openly acknowledged frustration with recent performance On-market capital management continued through this week The annual meeting in October looms as the next test CSL Limited (ASX:CSL) has kept retiring its own shares on market this week, lodging daily updates on its capital management program days after its annual report conceded that owners of the stock are frustrated and that the biotech giant was slow to adapt to competitive pressures. An unusually blunt admission ...

Continue reading
Kalkine
Neutral
24 Sept

What Does the Latest Update Mean for CSL Ltd (ASX:CSL) as a Bluechip Stock?

Highlights A softer global equity tone is likely to increase attention on relative resilience across ASX sectors. CSL Ltd is assessed through the current blue-chip shares backdrop rather than a directional share-price call. Operational adaptability and leadership, liquidity and operating durability are the main themes to monitor. The ASX is confronting a more volatile cross-asset backdrop as higher yields and energy prices challenge sentiment. That makes CSL Ltd (ASX:CSL) a timely case study ...

Continue reading
Kalkine
Neutral
23 Sept

What could CSL (ASX:CSL) Repurchase Update Mean?

Highlights CSL has released a fresh notification concerning its ongoing on-market share repurchase programme. The disclosure adds a current corporate-action checkpoint for readers tracking the major Australian healthcare company. Further company notifications will provide the clearest record of how the repurchase programme progresses. A fresh corporate action can quickly bring a major ASX-listed company back into focus, particularly when the disclosure concerns an ongoing share repurchas...

Continue reading
Kalkine
Neutral
23 Sept

Could Expanded Drug Coverage Change CSL’s (ASX:CSL) Story?

Highlights Expanded reimbursement access for ANDEMBRY adds to CSLs commercial development in hereditary angioedema. CSL (ASX:CSL) continues to develop ANDEMBRY alongside its broader plasma and specialty medicines portfolio. Canadian reimbursement decisions provide another example of how regulatory and payer access can affect the reach of a healthcare product. CSLs latest developments around ANDEMBRY have placed attention on the relationship between pharmaceutical development, regulatory access...

Continue reading
Kalkine
Neutral
22 Sept

Could CSL (ASX:CSL) Stay a Bluechip Stocks Cornerstone?

Highlights CSL (ASX:CSL) operates a global plasma therapeutics business alongside its Seqirus vaccine division. Its international manufacturing footprint anchors its position within Bluechip Stocks. Research and development investment continues to shape its long-term pipeline. Few names carry as much weight within Australia's healthcare sector as CSL (ASX:CSL). Built around plasma collection and its Seqirus vaccine arm, CSL sits at the centre of Bluechip Stocks, offering broad exposure across...

Continue reading
Kalkine
Neutral
21 Sept

What Does CSL Limited (ASX:CSL) Capital Return Program Mean for Bluechip Stocks?

Highlights CSL Limited (ASX:CSL) has disclosed a capital return program update that adds a new point to its public record. The update is most relevant through scale, recurring demand, governance, capital allocation and the operating resilience expected from large established companies, with the company-specific detail remaining central. Further disclosure will help establish how the stated milestone develops and what operational or governance steps follow. Why the latest disclosure matters A ...

Continue reading
Kalkine
Neutral
20 Sept

Why Did CSL Shares Rise as Healthcare Led the ASX 200?

Highlights CSL (ASX:CSL) rose considerably last week as the ASX 200 Health Care Index outperformed the broader market CSL shares are up substantially since early June 2026, well ahead of the broader market's recent weekly tone Markets are pricing a high probability of another rate hike at the end of the month, with attention on CSL centred on healthcare resilience CSL (ASX:CSL) stock rose considerably last week as the S&P/ASX 200 Health Care Index gained solidly, while the broader S&P/...

Continue reading
Kalkine
Neutral
20 Sept

What Does Catapult Wealth Think of Coles, CSL and NAB Shares?

Highlights Dylan Evans from Catapult Wealth holds a constructive rating on Coles Group (ASX:COL), backed by favourable supermarket industry dynamics CSL (ASX:CSL) draws a neutral rating, with recent guidance offering renewed confidence after a difficult period National Australia Bank (ASX:NAB) draws a cautious rating, with Evans flagging limited near-term growth catalysts S&P/ASX 200 Index shares edged modestly lower last week. On The Bull this week, Dylan Evans from Catapult Wealth explai...

Continue reading
Kalkine
Neutral
19 Sept

Is CSL Still Trading Below Its Estimated Value Despite Its Recent Rebound?

Highlights CSL (ASX:CSL) has openly acknowledged frustration with its weaker commercial and financial outcomes, pledging urgent investment in its core plasma operations The stock has climbed sharply over the past 90 days, though longer-term shareholder returns remain firmly negative The most popular valuation narrative suggests the shares remain undervalued despite this recent rebound CSL (ASX:CSL) has put shareholder concerns front and centre after its board openly acknowledged frustration wi...

Continue reading
Kalkine
Positive
18 Sept

CSL Shares (ASX:CSL) Surge: Is This ASX Healthcare Turnaround Real?

Highlights CSL shares have moved back into positive territory for the year after a sharp recovery from earlier weakness. The latest full-year result highlighted resilient underlying earnings and a stronger outlook for the coming financial year. Technical momentum has improved, although elevated RSI conditions point to the possibility of near-term consolidation. CSL shares (ASX:CSL) have staged a striking turnaround on the Australian share market, transforming a year of heavy pressure int...

Continue reading
Kalkine
Neutral
18 Sept

Why Is CSL Limited (ASX:CSL) in Focus on Today’s ASX Technical Screen?

Highlights CSL Limited is in focus after healthcare shares were among the notable gainers in todays ASX session. The same-day development puts attention on biotechnology leadership and market momentum within ASX Technical Analysis. Further relevance will depend on execution, follow-up disclosure and the next verifiable milestone. CSL Limited (ASX:CSL) [ASX 200] is drawing attention in todays Australian market cycle after healthcare shares were among the notable gainers in todays ASX session. ...

Continue reading
Kalkine
Neutral
17 Sept

Why Are Aurelia Metals and CSL Leading Today's ASX Uptrends?

Highlights Aurelia Metals (ASX:AMI) and CSL (ASX:CSL) both feature among today's standout uptrend charts Flight Centre (ASX:FLT), Hub24 (ASX:HUB) and Wisetech Global (ASX:WTC) all feature among today's weaker downtrend charts Gold, resources and select healthcare names continue to dominate the stronger end of today's technical scans Australian trading floors are showing a fresh divergence in momentum today, with Aurelia Metals (ASX:AMI) and CSL (ASX:CSL) both featuring prominently among today'...

Continue reading